164 related articles for article (PubMed ID: 8911695)
21. [Effect of pranlukast on histamine release and leukotriene c4 (ltc4) generation from human peripheral basophils].
Ito R; Miura K; Odajima Y; Shimamura T
Arerugi; 2004 Jan; 53(1):19-23. PubMed ID: 14762327
[TBL] [Abstract][Full Text] [Related]
22. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
23. Natural and recombinant enzymatically active or inactive bee venom phospholipase A2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy.
Förster E; Dudler T; Gmachl M; Aberer W; Urbanek R; Suter M
J Allergy Clin Immunol; 1995 Jun; 95(6):1229-35. PubMed ID: 7541059
[TBL] [Abstract][Full Text] [Related]
24. Changes in intracellular cyclic adenosine monophosphate levels in peripheral blood leukocytes during immunotherapy with vespid venom.
Bauer C; Przybilla B; Eberlein B; Kolsouzidou S; Ruëff F
Ann Allergy Asthma Immunol; 2007 Mar; 98(3):281-5. PubMed ID: 17378261
[TBL] [Abstract][Full Text] [Related]
25. Basophil activation can predict clinical sensitivity in patients after venom immunotherapy.
Kucera P; Cvackova M; Hulikova K; Juzova O; Pachl J
J Investig Allergol Clin Immunol; 2010; 20(2):110-6. PubMed ID: 20461965
[TBL] [Abstract][Full Text] [Related]
26. Regulatory T cells in children undergoing rush venom immunotherapy.
Ajduk J; Turkalj M; Gagro A
Allergy Asthma Proc; 2012; 33(6):525-30. PubMed ID: 23394512
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of immunotherapy to wasp and bee venom.
Ozdemir C; Kucuksezer UC; Akdis M; Akdis CA
Clin Exp Allergy; 2011 Sep; 41(9):1226-34. PubMed ID: 21729181
[TBL] [Abstract][Full Text] [Related]
28. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of arachidonic acid generation in human basophils: relationship between the effects of inhibitors of secretory phospholipase A2 activity and leukotriene C4 release.
Hundley TR; Marshall LA; Hubbard WC; MacGlashan DW
J Pharmacol Exp Ther; 1998 Mar; 284(3):847-57. PubMed ID: 9495842
[TBL] [Abstract][Full Text] [Related]
30. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.
Patella V; Bouvet JP; Marone G
J Immunol; 1993 Nov; 151(10):5685-98. PubMed ID: 7693815
[TBL] [Abstract][Full Text] [Related]
31. Increased specificity of diagnostic tests with recombinant major bee venom allergen phospholipase A2.
Müller U; Fricker M; Wymann D; Blaser K; Crameri R
Clin Exp Allergy; 1997 Aug; 27(8):915-20. PubMed ID: 9291289
[TBL] [Abstract][Full Text] [Related]
32. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
33. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
34. Regulation and kinetics of platelet-activating factor and leukotriene C4 synthesis by activated human basophils.
Lie WJ; Homburg CH; Kuijpers TW; Knol EF; Mul FP; Roos D; Tool AT
Clin Exp Allergy; 2003 Aug; 33(8):1125-34. PubMed ID: 12911788
[TBL] [Abstract][Full Text] [Related]
35. The frequency of phospholipase A2 binding of basophilic granulocytes does not decrease during bee-venom-specific immunotherapy.
Irsch J; König C; Löhndorf A; Tesch H; Krieg T; Merk H; Radbruch A; Hunzelmann N
Allergy; 1999 Jul; 54(7):742-7. PubMed ID: 10442531
[TBL] [Abstract][Full Text] [Related]
36. Review of venom immunotherapy at a regional tertiary paediatric centre.
Johnston N; Belcher J; Preece K; Bhatia R
J Paediatr Child Health; 2022 Jul; 58(7):1228-1232. PubMed ID: 35416342
[TBL] [Abstract][Full Text] [Related]
37. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
[TBL] [Abstract][Full Text] [Related]
38. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils.
Columbo M; Horowitz EM; Botana LM; MacGlashan DW; Bochner BS; Gillis S; Zsebo KM; Galli SJ; Lichtenstein LM
J Immunol; 1992 Jul; 149(2):599-608. PubMed ID: 1378071
[TBL] [Abstract][Full Text] [Related]
39. Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression.
Michils A; Mairesse M; Ledent C; Gossart B; Baldassarre S; Duchateau J
J Allergy Clin Immunol; 1998 Jul; 102(1):118-26. PubMed ID: 9679855
[TBL] [Abstract][Full Text] [Related]
40. Venom immunotherapy: clinical efficacy, safety and contraindications.
Kosnik M; Korosec P
Expert Rev Clin Immunol; 2015; 11(8):877-84. PubMed ID: 26018865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
